Pharvaris falls as Q4 loss widens
Brief: Pharvaris Reports Fourth Quarter Financial Results
Brief: Pharvaris Says Positive Phase 2 Data From Rapide-1 Study Of Phvs416 For On-Demand Treatment Of HAE Attacks Highlighted At 2023 HAEi Regional Conference Apac
Brief: Pharvaris To Highlight Positive Phase 2 Data From RAPIDe-1 Study Of PHVS416 For The On-Demand Treatment Of HAE Attacks At AAAAI Annual Meeting
Brief: Pharvaris Provides Clinical And Corporate Updates
U.S. STOCKS ON THE MOVE-Regenxbio, Hello Group, copper miners
Pharvaris soars as drug meets goals in mid-stage study
U.S. STOCKS ON THE MOVE-Express, Hershey, Entrada Therapeutics
U.S. STOCKS ON THE MOVE-Rent the Runway, Pharvaris, U.S. energy firms
Brief: Pharvaris Announces Positive Top-Line Phase 2 Data From RAPIDe-1 Study Of PHVS416 For The On-Demand Treatment Of HAE Attacks
Brief: Pharvaris Reports Third Quarter 2022 Financial Results And Provides Business Update
Pharvaris rises as drug meets goals in mid-stage study
Pharvaris NV reports results for the quarter ended in September - Earnings Summary
Pharvaris NV expected to post a loss of 63 cents a share - Earnings Preview
Pharvaris NV expected to post a loss of 63 cents a share - Earnings Preview
Pharvaris NV expected to post a loss of 63 cents a share - Earnings Preview
Pharvaris NV expected to post a loss of 63 cents a share - Earnings Preview
Pharvaris NV expected to post a loss of 63 cents a share - Earnings Preview
Pharvaris NV expected to post a loss of 63 cents a share - Earnings Preview